Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Diabetes

  Free Subscription


Articles published in Circulation

Retrieve available abstracts of 78 articles:
HTML format



Single Articles


    March 2024
  1. BILLING AM, Kim YC, Gullaksen S, Schrage B, et al
    Metabolic Communication by SGLT2 Inhibition.
    Circulation. 2024;149:860-884.
    PubMed     Abstract available


  2. GABA P, Sabik JF, Murphy SA, Bellavia A, et al
    Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials.
    Circulation. 2024 Mar 11. doi: 10.1161/CIRCULATIONAHA.123.065571.
    PubMed     Abstract available


    February 2024
  3. GREEN JB, Everett BM, Ghosh A, Younes N, et al
    Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
    Circulation. 2024 Feb 12. doi: 10.1161/CIRCULATIONAHA.123.066604.
    PubMed     Abstract available


    January 2024
  4. LI Y, Liu Z, Han X, Liang F, et al
    Dynamics of Endothelial Cell Generation and Turnover in Arteries During Homeostasis and Diseases.
    Circulation. 2024;149:135-154.
    PubMed     Abstract available


    December 2023
  5. OSTERGAARD L, Olesen JB, Petersen JK, Nielsen LS, et al
    Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA(2)DS(2)-VASc 1: A Nationwide Study.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477.
    PubMed     Abstract available


  6. ZHAN J, Jin K, Xie R, Fan J, et al
    Ago2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation.
    Circulation. 2023 Dec 21. doi: 10.1161/CIRCULATIONAHA.123.065546.
    PubMed     Abstract available


  7. GALLAGHER KA, Mills JL, Armstrong DG, Conte MS, et al
    Current Status and Principles for the Treatment and Prevention of Diabetic Foot Ulcers in the Cardiovascular Patient Population: A Scientific Statement From the American Heart Association.
    Circulation. 2023 Dec 14. doi: 10.1161/CIR.0000000000001192.
    PubMed     Abstract available


    November 2023
  8. XIE SY, Liu SQ, Zhang T, Shi WK, et al
    USP28 Serves as a Key Suppressor of Mitochondrial Morphofunctional Defects and Cardiac Dysfunction in the Diabetic Heart.
    Circulation. 2023 Nov 23. doi: 10.1161/CIRCULATIONAHA.123.065603.
    PubMed     Abstract available


  9. NEUEN BL, Heerspink HJL, Vart P, Claggett BL, et al
    Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
    Circulation. 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.067584.
    PubMed     Abstract available


  10. PATEL KV, Segar MW, Klonoff DC, Khan MS, et al
    Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis.
    Circulation. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067530.
    PubMed     Abstract available


    September 2023
  11. JEX N, Greenwood JP, Cubbon RM, Rider OJ, et al
    Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis.
    Circulation. 2023 Sep 25. doi: 10.1161/CIRCULATIONAHA.122.063444.
    PubMed     Abstract available


    August 2023
  12. JANUZZI JL, Mohebi R, Liu Y, Sattar N, et al
    Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
    Circulation. 2023;148:651-660.
    PubMed     Abstract available


  13. BORLAUG BA, Reddy YNV, Braun A, Sorimachi H, et al
    Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
    Circulation. 2023 Aug 3. doi: 10.1161/CIRCULATIONAHA.123.065134.
    PubMed     Abstract available


    June 2023
  14. OZKAN B, Ndumele CE
    Addressing Cardiovascular Risk in Diabetes: It's More Than the Sugar.
    Circulation. 2023;147:1887-1890.
    PubMed    



  15. Correction to: Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
    Circulation. 2023;147:e720.
    PubMed    


    May 2023
  16. KWAN TW, Wong SS, Hong Y, Kanaya AM, et al
    Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association.
    Circulation. 2023 May 8. doi: 10.1161/CIR.0000000000001145.
    PubMed     Abstract available


  17. SATTAR N, McMurray J, Boren J, Rawshani A, et al
    Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study.
    Circulation. 2023 May 8. doi: 10.1161/CIRCULATIONAHA.122.063374.
    PubMed     Abstract available


    April 2023
  18. SADOSHIMA J
    Caveolin-3 Nitration Drives Insulin Resistance in Prediabetic Hearts.
    Circulation. 2023;147:1180-1182.
    PubMed    


  19. WONG EKC, Demers C
    Letter by Wong and Demers Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
    Circulation. 2023;147:1118.
    PubMed    


    March 2023
  20. HINKLE SN, Schisterman EF, Liu D, Pollack AZ, et al
    Pregnancy Complications and Long-Term Mortality in a Diverse Cohort.
    Circulation. 2023;147:1014-1025.
    PubMed     Abstract available


  21. TABAK AG, Sattar N, Kivimaki M
    Response by Tabak et al to Letters Regarding Article, "Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study".
    Circulation. 2023;147:988-989.
    PubMed    


  22. DENG L, Chen Y, Deng W
    Letter by Deng et al Regarding Article, "Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study".
    Circulation. 2023;147:985-986.
    PubMed    


  23. SCHMIDT MI, Bracco PA, Duncan BB
    Letter by Schmidt et al Regarding Article, "Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study".
    Circulation. 2023;147:987.
    PubMed    


  24. MENG Z, Zhang Z, Zhao J, Liu C, et al
    Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target Against Ischemic Heart Failure in Prediabetic Animals.
    Circulation. 2023 Mar 8. doi: 10.1161/CIRCULATIONAHA.122.063073.
    PubMed     Abstract available


  25. VERMA S, Alamuddin N, Alawadi F, Alkandari H, et al
    Prevalence of Diabetes and Cardiovascular Risk in the Middle East and Africa: Primary Results of the PACT-MEA Study.
    Circulation. 2023 Mar 6. doi: 10.1161/CIRCULATIONAHA.123.064345.
    PubMed    


  26. HAHN VS, Petucci C, Kim MS, Bedi KC Jr, et al
    Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023 Mar 1. doi: 10.1161/CIRCULATIONAHA.122.061846.
    PubMed     Abstract available


    February 2023
  27. GERSTEIN HC, Li Z, Ramasundarahettige C, Baek S, et al
    Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
    Circulation. 2023 Feb 20. doi: 10.1161/CIRCULATIONAHA.122.063716.
    PubMed     Abstract available


  28. SAWAMI K, Tanaka A, Node K
    Letter by Sawami et al Regarding Article, "Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)".
    Circulation. 2023;147:e73-e74.
    PubMed    


    January 2023
  29. CHEN S, Wang Q, Christodoulou A, Mylonas N, et al
    Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.
    Circulation. 2023;147:276-279.
    PubMed    


    December 2022
  30. GYLDENKERNE C, Maeng M, Kjoller-Hansen L, Maehara A, et al
    Coronary Artery Lesion Lipid Content and Plaque Burden in Diabetic and Nondiabetic Patients: PROSPECT II.
    Circulation. 2022 Dec 16. doi: 10.1161/CIRCULATIONAHA.122.061983.
    PubMed     Abstract available


  31. SCHOLTES RA, Hesp AC, Mosterd CM, Geurts F, et al
    Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes.
    Circulation. 2022;146:1895-1897.
    PubMed    


  32. MARX N, Husain M, Lehrke M, Verma S, et al
    GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
    Circulation. 2022;146:1882-1894.
    PubMed     Abstract available


    November 2022
  33. GAO P, Cao M, Jiang X, Wang X, et al
    Cannabinoid Receptor 2-Centric Molecular Feedback Loop Drives Necroptosis in Diabetic Heart Injuries.
    Circulation. 2022 Nov 30. doi: 10.1161/CIRCULATIONAHA.122.059304.
    PubMed     Abstract available


  34. TONELLI M, Straus S
    Increasing Societal Benefit From Cardiovascular Drugs.
    Circulation. 2022;146:1627-1635.
    PubMed     Abstract available


  35. VERMA S, Dhingra NK, Butler J, Anker SD, et al
    Empagliflozin in Black Versus White Patients with Heart Failure: Analysis of EMPEROR-Pooled.
    Circulation. 2022 Nov 7. doi: 10.1161/CIRCULATIONAHA.122.062644.
    PubMed    


  36. WANG X, Vaduganathan M, Claggett BL, Hegde SM, et al
    Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER.
    Circulation. 2022 Nov 7. doi: 10.1161/CIRCULATIONAHA.122.062832.
    PubMed     Abstract available


  37. CONNELLY KA, Mazer CD, Puar P, Teoh H, et al
    Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
    Circulation. 2022 Nov 6. doi: 10.1161/CIRCULATIONAHA.122.062769.
    PubMed     Abstract available


  38. PACKER M
    Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis.
    Circulation. 2022;146:1383-1405.
    PubMed     Abstract available


    October 2022
  39. GAZIANO L, Sun L, Arnold M, Bell S, et al
    Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses.
    Circulation. 2022 Oct 31. doi: 10.1161/CIRCULATIONAHA.122.060700.
    PubMed     Abstract available


  40. ZWECK E, Scheiber D, Schultheiss HP, Kuss O, et al
    Impaired Myocardial Mitochondrial Respiration in Humans With Prediabetes: A Footprint of Prediabetic Cardiomyopathy.
    Circulation. 2022;146:1189-1191.
    PubMed    


    September 2022
  41. JIN L, Geng L, Ying L, Shu L, et al
    FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity.
    Circulation. 2022 Sep 22:101161CIRCULATIONAHA122059631.
    PubMed     Abstract available


    August 2022
  42. TABAK AG, Brunner EJ, Lindbohm JV, Singh-Manoux A, et al
    Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study.
    Circulation. 2022 Aug 25:101161CIRCULATIONAHA122059430.
    PubMed     Abstract available


  43. COSENTINO F, Cannon CP, Frederich R, Cherney DZI, et al
    Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
    Circulation. 2022;146:652-654.
    PubMed    


  44. UMANATH K, Testani JM, Lewis JB
    "Dip" in eGFR: Stay the Course With SGLT-2 Inhibition.
    Circulation. 2022;146:463-465.
    PubMed    


    July 2022
  45. ANKER SD, Usman MS, Butler J
    SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy.
    Circulation. 2022;146:299-302.
    PubMed    


  46. LEE MMY, Gillis KA, Brooksbank KJM, Allwood-Spiers S, et al
    Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
    Circulation. 2022;146:364-367.
    PubMed    


  47. O'SULLIVAN JW, Raghavan S, Marquez-Luna C, Luzum JA, et al
    Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association.
    Circulation. 2022 Jul 18:101161CIR0000000000001077.
    PubMed     Abstract available


  48. LAM CSP, Gerstein HC
    Response by Lam and Gerstein to Letter Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial".
    Circulation. 2022;146:e7.
    PubMed    


  49. GROOTHOF D, Post A, Bakker SJL
    Letter by Groothof et al Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial".
    Circulation. 2022;146:e5-e6.
    PubMed    


  50. EICHELMANN F, Sellem L, Wittenbecher C, Jager S, et al
    Deep Lipidomics in Human Plasma: Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation.
    Circulation. 2022;146:21-35.
    PubMed     Abstract available


    June 2022
  51. SCHULZE PC, Bogoviku J, Westphal J, Aftanski P, et al
    Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
    Circulation. 2022 Jun 29:101161CIRCULATIONAHA122059038.
    PubMed     Abstract available


  52. FILIPPATOS G, Butler J, Farmakis D, Zannad F, et al
    Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
    Circulation. 2022 Jun 28:101161CIRCULATIONAHA122059785.
    PubMed     Abstract available


  53. RAWSHANI A, Sattar N, McGuire DK, Wallstrom O, et al
    Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 Diabetes.
    Circulation. 2022 Jun 9. doi: 10.1161/CIRCULATIONAHA.121.058072.
    PubMed     Abstract available


    May 2022
  54. GERSTEIN HC
    Shouldn't Preventing Type 2 Diabetes Also Prevent Its Long-Term Consequences?
    Circulation. 2022;145:1642-1644.
    PubMed    


  55. GOLDBERG RB, Orchard TJ, Crandall JP, Boyko EJ, et al
    Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.
    Circulation. 2022 May 23. doi: 10.1161/CIRCULATIONAHA.121.056756.
    PubMed    


  56. SELVARAJ S, Fu Z, Jones P, Kwee LC, et al
    Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF.
    Circulation. 2022 May 23. doi: 10.1161/CIRCULATIONAHA.122.060402.
    PubMed     Abstract available


  57. FURTADO RHM, Raz I, Goodrich EL, Murphy SA, et al
    Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
    Circulation. 2022 May 5. doi: 10.1161/CIRCULATIONAHA.121.058103.
    PubMed     Abstract available


    April 2022
  58. ADAMSON C, Docherty KF, Heerspink HJL, de Boer RA, et al
    Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF.
    Circulation. 2022 Apr 20. doi: 10.1161/CIRCULATIONAHA.121.058910.
    PubMed     Abstract available


  59. VASAN RS, Enserro DM, Xanthakis V, Beiser AS, et al
    Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study.
    Circulation. 2022 Apr 18. doi: 10.1161/CIRCULATIONAHA.121.057889.
    PubMed     Abstract available


  60. NEUEN BL, Oshima M, Agarwal R, Arnott C, et al
    Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.
    Circulation. 2022 Apr 8. doi: 10.1161/CIRCULATIONAHA.121.057736.
    PubMed     Abstract available


  61. SLIZ E, Shin J, Ahmad S, Williams DM, et al
    Circulating Metabolome and White Matter Hyperintensities in Women and Men.
    Circulation. 2022;145:1040-1052.
    PubMed     Abstract available


    March 2022
  62. CORTES V, Eckel RH
    Insulin and Bile Acids in Cholesterol Homeostasis: New Players in Diabetes-Associated Atherosclerosis.
    Circulation. 2022;145:983-986.
    PubMed    


    February 2022
  63. SEMOVA I, Levenson AE, Krawczyk J, Bullock K, et al
    Insulin Prevents Hypercholesterolemia by Suppressing 12a-Hydroxylated Bile Acid Production.
    Circulation. 2022 Feb 23. doi: 10.1161/CIRCULATIONAHA.120.045373.
    PubMed     Abstract available



  64. Correction to: Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
    Circulation. 2022;145:e641.
    PubMed    


    January 2022
  65. JOSEPH JJ, Deedwania P, Acharya T, Aguilar D, et al
    Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association.
    Circulation. 2022 Jan 10:CIR0000000000001040. doi: 10.1161/CIR.0000000000001040.
    PubMed     Abstract available


    December 2021
  66. SHAMAN AM, Bain SC, Bakris GL, Buse JB, et al
    Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials.
    Circulation. 2021 Dec 14. doi: 10.1161/CIRCULATIONAHA.121.055459.
    PubMed     Abstract available


  67. PATEL KV, Segar MW, Lavie CJ, Kondamudi N, et al
    Diabetes Status Modifies the Association Between Different Measures of Obesity and Heart Failure Risk Among Older Adults: A Pooled Analysis of Community-Based NHLBI Cohorts.
    Circulation. 2021 Dec 3. doi: 10.1161/CIRCULATIONAHA.121.055830.
    PubMed     Abstract available


    November 2021
  68. LAM CSP, Ramasundarahettige C, Branch KRH, Sattar N, et al
    Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
    Circulation. 2021 Nov 14. doi: 10.1161/CIRCULATIONAHA.121.057934.
    PubMed     Abstract available


  69. FILIPPATOS G, Anker SD, Agarwal R, Ruilope LM, et al
    Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial.
    Circulation. 2021 Nov 13. doi: 10.1161/CIRCULATIONAHA.121.057983.
    PubMed     Abstract available


    October 2021
  70. MAJITHIA A, Bhatt DL, Friedman AN, Miller M, et al
    Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
    Circulation. 2021 Oct 28. doi: 10.1161/CIRCULATIONAHA.121.055560.
    PubMed     Abstract available


    September 2021
  71. EDGAR L, Akbar N, Braithwaite AT, Krausgruber T, et al
    Hyperglycemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis.
    Circulation. 2021;144:961-982.
    PubMed     Abstract available


    June 2021
  72. MORRIS AA, Testani JM, Butler J
    Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities.
    Circulation. 2021;143:2329-2331.
    PubMed    


    March 2021
  73. PATEL RB, Ter Maaten JM, Ferreira JP, McCausland FR, et al
    Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials.
    Circulation. 2021;143:949-958.
    PubMed     Abstract available


    February 2021
  74. GOFF DC JR, Khan SS, Lloyd-Jones D, Arnett DK, et al
    Bending the Curve in Cardiovascular Disease Mortality: Bethesda + 40 and Beyond.
    Circulation. 2021;143:837-851.
    PubMed     Abstract available


    January 2021
  75. VIRANI SS, Alonso A, Aparicio HJ, Benjamin EJ, et al
    Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.
    Circulation. 2021 Jan 27:CIR0000000000000950. doi: 10.1161/CIR.0000000000000950.
    PubMed     Abstract available


  76. KOSIBOROD M
    Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.
    Circulation. 2021;143:350-353.
    PubMed    


  77. PETERSON BE, Bhatt DL, Steg PG, Miller M, et al
    Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
    Circulation. 2021;143:33-44.
    PubMed     Abstract available


    August 2020
  78. MORDI NA, Mordi IR, Singh JS, McCrimmon RJ, et al
    Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Circulation. 2020 Aug 29. doi: 10.1161/CIRCULATIONAHA.120.048739.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.